Research shows a promising new method to reduce graft-versus-host-disease after bone marrow transplantation

October 13, 2010

(PhysOrg.com) -- University of Michigan researchers have discovered a new method to prevent the immune-system attacks that often occur following bone marrow transplants.

Bone marrow transplantation can cure patients with leukemia and other cancers even when the disease is resistant to other treatments. The success of this procedure relies on killing cancer cells by using from a bone marrow donor while avoiding an against the patient's organs, which causes a dangerous complication called graft-versus-host disease.

Dr. Ivan Maillard, a U-M Life Sciences Institute professor and an assistant professor of internal medicine at the Medical School, and his lab discovered the new method and say they're encouraged by preliminary results in mouse models. The work, done in collaboration with a team at the U-M Comprehensive Cancer Center, was recently reported in the journal Blood.

The new method works by inhibiting the Notch signaling pathway in immune cells called donor . "Notch is an important pathway that researchers have started to identify multiple functions for in normal tissues and in cancer," said Maillard.

The research team found that Notch-deficient T cells had a markedly reduced ability to produce inflammatory mediators and to damage the normal organs of the recipient mice.

However, unlike previous interventions, Notch inhibition had selective effects and did not cause global immunosuppression. In particular, the Notch-deficient T cells remained able to efficiently kill . This resulted in the elimination of the tumor cells without causing life-threatening graft-versus-host disease.

The LSI team is excited by the future prospects brought by this discovery. In particular, an expanding set of reagents is being developed to target components of Notch signaling that can someday be developed into effective new therapies for patients.

This work was supported by an Innovation Award from the Damon Runyon Cancer Research Foundation, the American Society of Hematology, and the University of Michigan Comprehensive Cancer Center.

More information: bloodjournal.hematologylibrary.org/papbyrecent.dtl

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.